Shots:
- OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels
- The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening
- As per the deal, OmniAb will receive an upfront payment & could earn ~$370M in research, development & commercial milestones, in addition to tiered royalties on global net sales of any resulting products
Ref: Businesswire | Image: OmniAb & Eli Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
